Pfizer,the world's largest pharmaceutical company,has acquired the developmental drug terguride from Ergonex Pharma GmbH.Terguride is in a Phase 2 Trial.It is an oral medication for the rare cardiovascular condition pulmonary arterial hypertension,which afflicts 100-200,000 people in Europe and the U.S.
In PAH,the arteries that carry blood from the heart to the lungs become thickened and constricted,forcing the heart to work harder to pump blood through the lungs.Eventually,the heart can no longer provide an adequate blood supply to the lungs,resulting in shortness of breath,fatigue,dizziness,fainting,chest pain,edema and even heart failure.
Terguride treats PAH by targeting the release of serotonin,an organic compound found in human and animal tissue.Although serotonin is beneficial in many ways,such as regulating cyclic body processes,it can also stimulate the proliferation of pulmonary artery smooth cells and cause fiber formation in the artery walls.Terguride offers the hope of reversing this arterial remodeling and slowing disease progression,Pfizer believes.
The agreement gives Pfizer exclusive worldwide rights-excluding Japan-to commercialize terguride for the treatment of PAH.Ergonex will receive milestone payments and royalties on sales of the drug.
Pfizer(PFE)
No comments:
Post a Comment